Merrimack Pharmaceuticals, Inc. (MACK) News

Merrimack Pharmaceuticals, Inc. (MACK): $15.13

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add MACK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#150 of 360

in industry

Filter MACK News Items

MACK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MACK News From Around the Web

Below are the latest news stories about MERRIMACK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MACK as an investment opportunity.

Merrimack Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass., November 02, 2023--Merrimack Reports Third Quarter 2023 Financial Results

Yahoo | November 2, 2023

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) most popular amongst retail investors who own 39% of the shares, institutions hold 33%

Key Insights Significant control over Merrimack Pharmaceuticals by retail investors implies that the general public has...

Yahoo | September 26, 2023

Merrimack Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., August 03, 2023--Merrimack Reports Second Quarter 2023 Financial Results

Yahoo | August 3, 2023

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Merrimack...

Yahoo | July 3, 2023

Merrimack Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass., May 04, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [("Merrimack" or the "Company")] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

Yahoo | May 4, 2023

Retail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%

Key Insights Significant control over Merrimack Pharmaceuticals by retail investors implies that the general public has...

Yahoo | April 19, 2023

Merrimack Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., March 09, 2023--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022.

Yahoo | March 9, 2023

Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, Merrimack Pharmaceuticals...

Yahoo | January 23, 2023

12 Best Performing Biotech Stocks in 2022

In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]

Yahoo | December 29, 2022

Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last year

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | December 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!